Clinical Outcomes of First-Line Pembrolizumab Monotherapy in Advanced NSCLC With PD-L1 Tumor Proportion Score of 1% to 49%: A Retrospective Multicenter Study.

In an exploratory analysis of the PD-L1 TPS 1% to 49% subgroup in the KEYNOTE-042 trial, OS was 13.4 months with pembrolizumab monotherapy versus 12.1 months with chemotherapy, but the difference did not reach statistical significance. 13 This lack of a clear survival advantage has led to uncertainty regarding the optimal first-line treatment approach for this population.

also in 111,027 other papers